About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Austin | 15,205 Studies Near You | Clareo Health

Clinical Trials LocationsAustin

Clinical Trials in Austin

Discover 15,205 clinical trials near Austin, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 13441-13460 of 15,205 trials

COMPLETEDPhase 3< 1 mile

Topical Antifungal Treatment for Tinea Cruris

NCT01342315

To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris

Medicis Global Service Corporation483 participantsStarted May 2011

Fremont, California, United States • Los Angeles, California, United States • Miami, Florida, United States +18 more locations

COMPLETEDPhase 359 miles

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399

The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.

Bacterial Vaginosis

Medicis Global Service Corporation651 participantsStarted May 2012

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Mesa, California, United States +34 more locations

Find Trials by Condition in Austin

Breast Cancerin Austin Lung Cancerin Austin Prostate Cancerin Austin Colorectal Cancerin Austin Melanomain Austin Leukemiain Austin Lymphomain Austin Pancreatic Cancerin Austin Ovarian Cancerin Austin Brain Cancerin Austin Diabetesin Austin

Data from ClinicalTrials.govTerms

COMPLETEDPhase 462 miles

Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)

NCT00726713

The purpose of this research study is to determine if Metanx improves sensory neuropathy in persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a physician. It consists of L-methylfolate, Pyridoxal 5'-phosphate, and Methylcobalamin, which are the active forms of folate, vitamin B6, and vitamin B12, respectively. Subjects will be randomly assigned to receive either Metanx or placebo for 6 months.

Type 2 Diabetic Peripheral Neuropathy (DPN)

Pamlab, Inc.214 participantsStarted Jun 2008

Birmingham, Alabama, United States • New Orleans, Louisiana, United States • Omaha, Nebraska, United States +3 more locations

TERMINATED74 miles

OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.

NCT00277524

The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants. This study will assess therapies in Medtronic pacemaker, defibrillator, and cardiac resynchronization therapy devices. The first therapy is for reducing unnecessary pacing in pacemaker patients. The second therapy provides pacing therapy in an attempt to stop fast or life threatening ventricular arrhythmias in lieu of delivering a defibrillation shock. The third therapy is a diagnostic measurement of a patient's fluid status and provides the physician information on the patient's heart failure status. The study will also assess the time to a patient's first defibrillation shock and will verify that the shock was for a fast or life threatening ventricular rhythm.

Tachycardia, VentricularHeart Failure, CongestiveVentricular Fibrillation+2 more

Medtronic Cardiac Rhythm and Heart Failure3,032 participantsStarted Aug 2005

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Fresno, California, United States +110 more locations

COMPLETEDPhase 474 miles

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

NCT00948766

The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm\^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm\^2 patch) in patients with Severe Dementia of the Alzheimer's Type in a 24-week study. The extension study obtained additional safety and efficacy data, as well as provided the higher dose rivastigmine patch to all patients who completed the core study for an additional 24 weeks.

Alzheimer's Disease

Novartis716 participantsStarted Jul 2009

Tempe, Arizona, United States • Tucson, Arizona, United States • Conway, Arkansas, United States +92 more locations

COMPLETEDPhase 374 miles

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582

Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.

Cushing's Syndrome

Corcept Therapeutics50 participantsStarted Dec 2007

Birmingham, Alabama, United States • Escondido, California, United States • Stanford, California, United States +14 more locations

COMPLETEDNA80 miles

Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence

NCT01932866

The purpose of this randomized, controlled study is to evaluate whether the knowledge of a personalized diabetes risk score affects adherence to a 12-week diet and exercise lifestyle change program in prediabetic patients. The intervention group will receive diabetes risk score results at the beginning of the twelve weeks, and the control group will not receive these results. Both groups will review their baseline and 12-week diabetes risk score results at the conclusion of the program and will be followed for an additional twelve weeks. Attendance rates and changes in weight, BMI, abdominal circumference, blood pressure, HgA1c, fasting blood glucose, cholesterol, and diabetes risk score will be compared between the groups.

Pre-diabetesDiabetes Risk ScoreMotivation

59th Medical Wing223 participantsStarted Jun 2010

Travis AFB, California, United States • Andrews Air Force Base Census Designated Place, Maryland, United States • Nellis Air Force Base, Nevada, United States +2 more locations

COMPLETEDPhase 2147 miles

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

NCT00219817

Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.

Cancer Cachexia

Helsinn Therapeutics (U.S.), Inc80 participantsStarted Jun 2005

Greenbrae, California, United States • Boston, Massachusetts, United States • New York, New York, United States +4 more locations

COMPLETEDPhase 3147 miles

RNS® System Pivotal Study

NCT00264810

The RNS® System Pivotal study is designed to assess safety and demonstrate that the RNS® System is effective as an adjunctive (add-on) therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures from no more than two foci (two areas of the brain) that are refractory (drug-resistant or hard-to-treat) to two or more antiepileptic medications. Patients continue to receive their epilepsy medications while participating in the study.

NeuroPace240 participantsStarted Dec 2005

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +29 more locations

COMPLETEDPhase 3147 miles

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

NCT00002812

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.

Children's Oncology Group2,078 participantsStarted Sep 1996

Long Beach, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +32 more locations

COMPLETEDPhase 2147 miles

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

NCT00684918

This protocol will evaluate the efficacy of obatoclax in older patients with previously untreated AML.

Gemin X18 participantsStarted Apr 2008

Chicago, Illinois, United States • Iowa City, Iowa, United States • Westwood, Kansas, United States +10 more locations

COMPLETEDPhase 2147 miles

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

NCT00003203

RATIONALE: Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining carboplatin and vincristine with radiation therapy followed by adjuvant chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy followed adjuvant chemotherapy in treating young patients who have newly diagnosed high-risk CNS embryonal tumors.

Brain TumorsCentral Nervous System TumorsNeuroblastoma

Children's Oncology Group168 participantsStarted Mar 1998

Long Beach, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +35 more locations

COMPLETEDPhase 3147 miles

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927

This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.

Small Cell Lung Cancer

GlaxoSmithKline760 participantsStarted Apr 2001

Hoover, Alabama, United States • Chula Vista, California, United States • Fountain Valley, California, United States +173 more locations

COMPLETEDPhase 2189 miles

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

NCT00267358

Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.

Cancer Cachexia

Helsinn Therapeutics (U.S.), IncStarted Nov 2005

Glendale, Arizona, United States • Bakersfield, California, United States • Encinitas, California, United States +16 more locations

COMPLETEDPhase 2360 miles

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00425932

The purpose of this study is to further investigate rituximab in the treatment of rheumatoid arthritis and to evaluate magnetic resonance imaging of the joints as a possible method to improve the evaluation of treatments.

Rheumatoid Arthritis

Gaylis, Norman B., M.D.60 participantsStarted Feb 2007

Fort Lauderdale, Florida, United States • Hollywood, Florida, United States • Miami, Florida, United States +3 more locations

COMPLETEDNA391 miles

The Evaluation of Infant Formulas Fed to Infants With Common Feeding Problems

NCT01934257

This clinical trial will determine if the formula given to infants experiencing fussiness, crying, cramping, gas, and/or diarrhea, is accepted and well tolerated and helps to resolve symptoms.

Common Infant Feeding Problems

Mead Johnson Nutrition296 participantsStarted Jun 1994

Aurora, California, United States • Modesto, California, United States • Savannah, Georgia, United States +16 more locations

COMPLETEDPhase 3636 miles

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00002816

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.

Children's Oncology Group120 participantsStarted Dec 1996

Long Beach, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +30 more locations

COMPLETEDPhase 3753 miles

Performance of the Hedrocel(R) Cervical Fusion Device

NCT00758758

The objective of this clinical investigation is to compare patients treated with Anterior Cervical Discectomy and Fusion (ACDF) using the Hedrocel Cervical Fusion Device, with a concurrent, randomized, control group receiving autologous iliac crest bone graft or allograft and test the hypothesis that ACDF with Hedrocel is non-inferior to ACDF with allograft or autologous bone graft.

Symptomatic Cervical Disc Disease

Zimmer Biomet231 participantsStarted Dec 2001

Los Angeles, California, United States • Clearwater, Florida, United States • Orlando, Florida, United States +10 more locations

TERMINATEDPhase 1/2790 miles

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT00862082

The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in patients with hepatocellular carcinoma. These include: * Hypoxia. Hepatocellular Carcinoma (HCC) is likely to demonstrate a level of hypoxia sufficient to activate PR104 to its active metabolites PR104H and PR104M. In addition, in preclinical models, sorafenib has been demonstrated to increase the degree of hypoxia in tumors following treatment. * Non-overlapping toxicity. PR104 and sorafenib do not share major toxicities. It is anticipated that both drugs can be administered at their full single agent dose when used in combination. * Aldo-keto reductase 1C3 (AKR1C3). HCC has been shown to express high levels of AKR1C3 which should lead to selective activation of PR104 within both hypoxic and oxic HCC cells. * Preclinical data. The use of sorafenib and PR104 alone and in combination in a hepatocellular carcinoma model demonstrates activity of PR104 as a single agent and increased activity when PR104 and sorafenib are used in combination. The current study will provide an estimate of the activity of PR104 in subjects with HCC. This information will prove valuable in defining the future clinical development of PR104, and in determining if PR104 has sufficient activity in HCC to warrant a larger phase III registration study in this indication. Primary objectives * Phase I: Determine the maximum tolerated dose (MTD) of PR104 when used in combination with standard dose sorafenib * Phase II: Estimate the response rate (RR) of PR104/sorafenib \[Note: Phase II was never initiated\] Secondary objectives * Evaluate survival * Evaluate Progression Free Survival (PFS) * Evaluate time to progression (TTP) * Evaluate safety * Evaluate the pharmacokinetics (PK) of sorafenib, PR104 and PR104 metabolites * Collect diagnostic biopsy samples for the determination of aldo-keto reductase 1C3 * Collect plasma samples for assessment of potential biomarkers of tumor hypoxia

Hepatocellular Carcinoma

Proacta, Incorporated14 participantsStarted Mar 2009

Tucson, Arizona, United States • La Jolla, California, United States • Orange, California, United States +14 more locations

COMPLETEDPhase 11500 miles

VivaGel™ in Healthy Young Women

NCT00331032

The purpose of this study is to test the safety and tolerability of a medication applied vaginally twice daily in females versus placebo (inactive substance). Study participants will include 60 women, ages 18-24, non-pregnant, previously sexually active, Human Immunodeficiency Virus (HIV) negative and sexually transmitted infection (STI) free, in San Francisco or Kisuma, Kenya. Each study participant will be followed for 14 days of product use and an additional 7 days for safety assessments. Study procedures will include a physical exam with a pap smear, urine testing, blood sample testing, and a colposcopy (exam of the vagina and cervix using a lighted magnifying instrument). Information learned from this study may help to develop a safe and effective medication that could prevent herpes simplex virus and HIV. Participants may be involved in study related procedures for up to 55 days.

Herpes Simplex II

National Institute of Allergy and Infectious Diseases (NIAID)56 participantsStarted Dec 2006

San Francisco, California, United States • Kisumu, Kenya

PreviousPage 673 of 761Next

Heart Diseasein Austin